Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:02 AM
Ignite Modification Date:
2025-12-25 @ 3:02 AM
NCT ID:
NCT06605833
Eligibility Criteria:
Inclusion Criteria:
* Written informed consent
* Age 18 years or older
* Confirmed diagnosis of melanoma
* Stage IIB or IIC or stage III or stage IV melanoma
* Previous immunotherapy with immune-checkpoint inhibitors (anti PD-(L)1 +/- anti CTLA-4) for melanoma
* On standard of care surveillance, at 2 to 10+ years following the completion of immunotherapy treatment
Exclusion Criteria:
* Medical or psychological condition that would preclude informed consent.
* Known contraindications to MRI, such as claustrophobia, pregnancy, or indwelling metallic implant which is not MR conditional
* Current active treatment with systemic therapy for any malignancy.
* Active treatment with systemic therapy for any malignancy started after the completion of immunotherapy for melanoma.
* Subjects unable to comply with the study or sample schedule.
* Planned participation in a drug trial receiving investigational agents.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06605833
Study Brief:
Protocol Section:
NCT06605833